The company said it plans to use the net proceeds for general corporate purposes, including for working capital and possible acquisitions.
The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.
Positive first quarter earnings reports lifted many stocks of life science tools firms even as the broader biotechnology market suffered.
The company said test volume rose 87 percent to 186,000 during the quarter.
The company said 571,000 people were screened for colon cancer with its noninvasive Cologuard test in 2017.
Armune, a University of Michigan spinout, owns licensing rights to protein biomarkers from the university for lung, breast, and prostate cancer.
Underwriter Merrill Lynch exercised in full the option to purchase up to an additional $90M in senior notes on top of a $600M notes offering announced last week.
A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.
A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.
Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.
In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more
